

CERVICAL CARCINOMA

1. **Specimen(s):** *list all specimens removed during case*
2. **Procedure(s):** *select all that apply*
 - a. [Loop electrical excision procedure (LEEP)]
 - b. [Large loop excision of the transformation zone (LLETZ)]
 - c. [Cold knife cone excision]
 - d. [Trachelectomy]
 - e. [Total abdominal hysterectomy]
 - f. [Radical hysterectomy]
 - g. [Pelvic exenteration]
 - a. [Bilateral salpingo-oophorectomy]
 - b. [Bilateral oophorectomy]
 - c. [Bilateral salpingectomy]
 - d. [Right salpingo-oophorectomy]
 - e. [Right oophorectomy]
 - f. [Right salpingectomy]
 - g. [Left salpingo-oophorectomy]
 - h. [Left oophorectomy]
 - i. [Left salpingectomy]
 - j. [Omentectomy]
 - k. [Peritoneal biopsies]
 - l. [Peritoneal washings]
 - h. [Other, <SPECIFY>]
3. **Sentinel Lymph Node Sampling:** *select whether or not sentinel lymph nodes were removed*
 - a. [Performed]
 - b. [Not performed]
 - c. [Not applicable]
 - d. [Cannot be determined]
4. **Regional Lymph Node Sampling:** *select whether or not regional lymph nodes were removed*
 - a. [Performed]
 - b. [Not performed]
 - c. [Not applicable]
 - d. [Cannot be determined]
5. **Specimen Integrity:** *document whether intact or received fragmented. This absolutely requires correlating with the operative report.*
6. **Primary Tumor Site:** *select all that apply*
 - a. [Left superior quadrant (12 to 3 o'clock)]
 - b. [Left inferior quadrant (3 to 6 o'clock)]

- c. [Right inferior quadrant (6 to 9 o'clock)]
 - d. [Right superior quadrant (9 to 12 o'clock)]
 - e. [Multicentric, <SPECIFY>]
 - f. [Circumferential]
 - g. [Other, <SPECIFY>]
 - h. [Cannot be determined]
7. **Tumor Size:** *provide greatest dimension and total dimensions*
- a. [Greatest dimension: <PROVIDE GREATEST DIMENSION>]
 - b. [Total dimensions: <PROVIDE ADDITIONAL]
 - c. [Cannot be determined]
8. **Histologic Type:** *select appropriate tumor type*
- a. [Squamous cell carcinoma, keratinizing type]
 - b. [Squamous cell carcinoma, non-keratinizing type]
 - c. [Squamous cell carcinoma, basaloid type]
 - d. [Squamous cell carcinoma, papillary type]
 - e. [Squamous cell carcinoma, lymphoepithelioma-like]
 - f. [Verrucous carcinoma]
 - g. [Adenocarcinoma, usual type (HPV-related)]
 - h. [Adenocarcinoma, gastric type (not HPV-related; includes minimal deviation adenocarcinoma)]
 - i. [Clear cell carcinoma]
 - j. [Serous carcinoma]
 - k. [Mesonephric carcinoma]
 - l. [Adenosquamous carcinoma]
 - m. [Adenoid basal cell carcinoma]
 - n. [Adenoid cystic carcinoma]
 - o. [Small cell carcinoma]
 - p. [Neuroendocrine carcinoma, low-grade]
 - q. [Neuroendocrine carcinoma, high-grade]
 - r. [Undifferentiated carcinoma]
 - s. [Carcinosarcoma (malignant mixed Mullerian tumor, MMT)]
 - t. [Carcinoma, not otherwise-specified]
 - u. [Other, <SPECIFY>]
9. **Histologic Grade:** *specify histologic grade of tumor*
- a. If squamous carcinoma, usual-type adenocarcinoma, gastric-type mucinous adenocarcinoma, mesonephric adenocarcinoma, adenosquamous carcinoma, use WHO three-tiered system:
 - i. [Well-differentiated (grade 1)]

- ii. [Moderately-differentiated (grade 2)]
 - iii. [Poorly-differentiated (grade 3)]
 - iv. [Other, <SPECIFY>]
 - b. If verrucous carcinoma, then use [well-differentiated (grade 1)]
 - c. If serous carcinoma, small cell carcinoma, clear cell carcinoma, or carcinosarcoma, then use [high-grade]
- 10. Stromal Invasion:** *specify presence of stromal invasion*
- a. [Absent]
 - b. [Present, <PROVIDE DEPTH OF INVASION>]
 - i. [< 33% cervical stromal thickness]
 - ii. [≥ 33% to < 66% cervical stromal thickness]
 - iii. [≥ 66% cervical stromal thickness]
- 11. Lymph-Vascular Space Invasion:** *state whether LVI is present*
- a. [Absent]
 - b. [Present]
 - c. [Suspicious]
 - d. [Cannot be determined]
- 12. Other Sites/Organs Involved:** *state whether there is disease outside the cervix*
- a. [Negative]
 - b. [Positive: <LIST OTHER ORGANS INVOLVED> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>]
- 13. Regional Lymph Node Status:** *provide total sentinel and non-sentinel lymph node status*
- a. *It is important to indicate how big the metastasis is because this affects staging.*
 - b. Sentinel Lymph Nodes:
 - i. [Not performed]
 - ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL # OF SENTINEL LYMPH NODES>]
 - iii. If there are lymph nodes with carcinoma:
 - 1. [Number of lymph nodes with metastasis greater than 0.02 cm (bigger than ITCs)]
 - 2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
 - 3. [State anatomic site of positive lymph node(s)]
 - 4. [State presence/absence of extranodal extension]
 - 5. [Give total number of sentinel lymph nodes]
 - c. Non-sentinel Lymph Nodes:
 - i. [Not performed]

- ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL # OF SENTINEL LYMPH NODES>]
 - iii. If there are lymph nodes with carcinoma:
 1. [Number of lymph nodes with metastasis greater than 0.02 cm (bigger than ITCs)]
 2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
 3. [State anatomic site of positive lymph node(s)]
 4. [State presence/absence of extranodal extension]
 5. [Give total number of non-sentinel lymph nodes]
 - d. Total Lymph Nodes:
 - i. [Not performed]
 - ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL LYMPH NODES>]
 - iii. If there are lymph nodes with carcinoma:
 1. [Number of lymph nodes with metastasis greater than 0.02 cm (bigger than ITCs)]
 2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
 3. [State anatomic site of positive lymph node(s)]
 4. [State presence/absence of extranodal extension]
 5. [Give grand total # of lymph nodes (i.e. sentinel + non-sentinel)]
14. **Cytology:** *state whether or not cytology was performed and results, include accession number*
- a. [Not performed]
 - b. [Performed]:
 - i. [Positive, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
 - ii. [Negative, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
15. **Surgical Margins:** *select all that apply*
- a. Endocervical margin:
 - i. [Endocervical margin: Negative for invasive and in-situ carcinoma]
 - ii. [Endocervical margin: Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]
 - iii. [Endocervical margin: Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]
 - b. Ectocervical margin:
 - i. [Ectocervical margin: Negative for invasive and in-situ carcinoma]
 - ii. [Ectocervical margin: Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]

- iii. [Ectocervical margin: Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]
- c. Deep margin:
 - i. [Deep margin: Negative for invasive and in-situ carcinoma]
 - ii. [Deep margin: Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]
 - iii. [Deep margin: Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]
- d. Other margins: (including parametrial soft tissue margins)
 - i. [Negative for invasive and in-situ carcinoma]
 - ii. [Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]
 - iii. [Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]

16. Pathologic Staging: *use AJCC and/or FIGO; refer to staging manuals*